Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2012
03/22/2012US20120071426 Methods and compositions for treating lung cancer
03/22/2012US20120071424 Pharmaceutical composition used in prophylaxis or treatment of hyperproliferative skin conditions and malignant melanomas comprising pachastrissamine as active ingredient
03/22/2012US20120071421 Therapy with clostridium perfringens enterotoxin to treat ovarian and uterine cancer
03/22/2012US20120071420 Modified t cell receptors and related materials and methods
03/22/2012US20120071419 Target-Specific Non-Antibody Protein and Method for Preparing the Same
03/22/2012US20120071418 Inhibitors of Human EZH2 and Methods of Use Thereof
03/22/2012US20120071417 Methods of inhibiting cancer cell growth with hdac inhibitors and methods of screening for hdac10 inhibitors
03/22/2012US20120071405 Composition of inhibiting pathological angiogenesis
03/22/2012US20120071399 Sulfation of wnt pathway proteins
03/22/2012US20120071394 Novel polypeptides and use thereof
03/22/2012US20120071393 Mutant CyaA Polypeptides and Polypeptide Derivatives Suitable for the Delivery of Immunogenic Molecules Into a Cell
03/22/2012US20120070521 Method of extraction from withania somnifera and one or more fractions containing pharmacologically active ingredients obtained therefrom
03/22/2012US20120070519 Method for extraction of fractions containing pharmacologically active ingredients with less cytotoxicity from one or more plants
03/22/2012US20120070514 Aromatase inhibitor
03/22/2012US20120070512 Substituted 6-(2-hydroxybenzylamino)purine Derivatives, Their Use as Medicaments and Compositions Containing These Derivatives
03/22/2012US20120070511 Mitochondrial inhibitors and uses thereof
03/22/2012US20120070505 Functional amphipilic molecule or macromolecule formulations with multiple compartments
03/22/2012US20120070502 Methods of treating cancer
03/22/2012US20120070486 Methods and compositions related to prefoldin and its regulation
03/22/2012US20120070462 Targeted Gene Delivery to Dendritic Cells
03/22/2012US20120070461 Use of myeloid cell biomarkers for the diagnosis of cancer
03/22/2012US20120070460 Dendritic cell modulatory molecule
03/22/2012US20120070450 Leukemia stem cell markers
03/22/2012US20120070449 Methods of treating inflammation
03/22/2012US20120070448 Anti-il-3ra antibody for use in treatment of blood tumor
03/22/2012US20120070444 IN VIVO SCREENING MODELS FOR TREATMENT OF isoQC-RELATED DISORDERS
03/22/2012US20120070442 Methods and compositions for treating cancer
03/22/2012US20120070441 Extracellular yaluronidase from streptomyces koganeiensis
03/22/2012US20120070440 Therapeutic use of anti-cs1 antibodies
03/22/2012US20120070438 Methods for Treating Melanoma
03/22/2012US20120070437 Method of identifying compounds that bind baff-r
03/22/2012US20120070436 Antigen-binding proteins
03/22/2012US20120070434 Antibodies containing therapeutic tpo/epo mimetic peptides
03/22/2012US20120070432 Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine
03/22/2012US20120070430 Identification of tumor-associated markers for diagnosis and therapy
03/22/2012US20120070424 Mutations on OAS1 Genes
03/22/2012US20120070416 Macrocyclic Proline Derived HCV Serine Protease Inhibitors
03/22/2012US20120070413 Method of treating cancer with substituted amide derivatives
03/22/2012US20120070410 Imidazolothiazole compounds and methods of use thereof
03/22/2012US20120070405 Uses of Modified ELR-CXC Chemokine G31P To Treat Cancer
03/22/2012US20120070404 Increasing cancer patient survival time by administration of dithio-containing compounds
03/22/2012US20120070390 Topical drug delivery system with dual carriers
03/22/2012US20120070386 Trehalulose-containing composition, its preparation and use
03/22/2012US20120070377 Compounds and biological materials and uses thereof
03/22/2012US20120070373 Method and compound for treatment of cancer using phosphorous-32 labeled dna
03/22/2012US20120070372 Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma
03/22/2012US20120070371 Low-Density Magnesium-Aluminum-Silicate (MAS) Microparticles for Radiotherapy and/or Radioimaging
03/22/2012US20120070370 Spiro 1,3,4-thiadiazoline derivatives as ksp inhibitors
03/22/2012US20120070369 Hif inhibitors and use thereof
03/22/2012US20120070368 Methods of Using C-Met Modulators
03/22/2012CA2812089A1 Inhibitors of pi3k-delta and methods of their use and manufacture
03/22/2012CA2812088A1 Phtalazine derivatives as jak1 inhibitors
03/22/2012CA2811501A1 Inhibitor of hmgb protein-mediated immune response activation, and screening method
03/22/2012CA2811494A1 Octreotide-modified nanomedicine for cancer treatment or cancer palliative care
03/22/2012CA2811208A1 Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof
03/22/2012CA2811186A1 High purity heparin and production method therefor
03/22/2012CA2810708A1 Fused heteroaryls and their uses
03/22/2012CA2810254A1 Hsp90 inhibitors for treating non-small cell lung cancers in wild-type egfr and/or kras patients
03/22/2012CA2810243A1 Formulations of guanylate cyclase c agonists and methods of use
03/22/2012CA2810094A1 Estrogen receptor modulators and uses thereof
03/21/2012EP2431403A1 Polymer conjugate of bioactive substance having hydroxy group
03/21/2012EP2431393A1 Anti-axl antibody
03/21/2012EP2431385A2 Combination therapy with chlorotoxin
03/21/2012EP2431376A1 Novel stable crystal of 1-(2'-cyano-2'-deoxy-beta -d-arabinofuranosyl)cytosine monohydrochloride
03/21/2012EP2431371A1 Thiophene derivatives
03/21/2012EP2431369A2 Carboline derivatives useful in the inhibition of angiogenesis
03/21/2012EP2431366A1 New chlorine e6-folic acid conjugated compound, preparation method thereof, and pharmaceutical composition containing the same for treatment of cancer
03/21/2012EP2431365A1 Azetidine compound and medicinal use thereof
03/21/2012EP2431364A1 Nuclear export inhibitors
03/21/2012EP2431361A1 Ascorbic acid aryl acetate/propionate ester, preparation method and pharmaceutical composition thereof
03/21/2012EP2431045A1 Pancreatic cancer therapy with a parvovirus
03/21/2012EP2431040A1 Pharmaceutical composition comprising chlorine e6-folic acid conjugated compound and chitosan for treatment of cancer
03/21/2012EP2431032A1 Anti-tumor agent comprising tegafur-gimeracil-oteracil potassium combination drug and oxaliplatin
03/21/2012EP2431029A2 Method of inhibiting prostate cancer cell proliferation
03/21/2012EP2430051A1 Compositions containing antibodies for treating cd5+ hla-dr+ b or t cell related diseases
03/21/2012EP2430050A1 Humanized axl antibodies
03/21/2012EP2430039A1 Ttk peptides and vaccines including the same
03/21/2012EP2430034A1 2'-fluoro arabino nucleosides and use thereof
03/21/2012EP2430030A1 Spiro 1,3,4-thiadiazoline derivatives as ksp inhibitors
03/21/2012EP2430026A1 Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
03/21/2012EP2430024A1 [1,2,4]triazolo [4,3-b]pyridazines as ligands of the androgen receptor
03/21/2012EP2430016A2 Inhibitors of inv(16) leukemia
03/21/2012EP2430013A1 Heteroaryl compounds as pikk inhibitors
03/21/2012EP2429574A1 Compositions and methods for treating hematologic cancers targeting the sirp - cd47 interaction
03/21/2012EP2429563A1 Peptide able to disrupt the protein complex between the his273 mutaded p53 protein and the oncosuppressive p73 protein in tumour cells and therapeutic uses thereof
03/21/2012EP2429562A1 Use of inclusion bodies as therapeutic agents
03/21/2012EP2429533A1 Sulphated hyaluronic acids as regulator agents of the cytokine activity
03/21/2012EP2429531A2 Use of lipid conjugates in the treatment of diseases associated with vasculature
03/21/2012EP2429527A1 New combination therapy in treatment of cancer and fibrotic diseases
03/21/2012EP2429524A1 Methods of treating proliferative diseases
03/21/2012EP2429520A1 New combination therapy in treatment of oncological and fibrotic diseases
03/21/2012EP2429516A2 Combination of a pbospboinositkle 3-ks ase inhibitor and an antidiabetic compound
03/21/2012EP2429515A1 New medicines for topic use based on sulfated hyaluronic acid as activating or inhibiting agent of the cytokine activity
03/21/2012EP2429509A1 Lycopene and resveratrol compositions for nk cell activation resulting in anti-neoplastic effect
03/21/2012EP2429508A1 Lycopene and resveratrol dietary supplement
03/21/2012EP2429498A2 New oral formulations for tetrapyrrole derivatives
03/21/2012EP2429493A1 Compositions and methods for drug delivery
03/21/2012EP2133335B9 Sphingosine compound, method for producing the same, and sphingomyelinase inhibitor
03/21/2012EP2018869B1 Licorice polyphenol preparation
03/21/2012EP1966244B1 Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130
1 ... 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 ... 2211